drugset
drugset / Trial / NCT04113668

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

NCT04113668 ↗

Phase 1 Completed 48 enrolled Bristol-Myers Squibb
Non-randomizedCrossoverOpen-labelDiagnostic

Summary

BMS-986165 Is broken down by the body through multiple pathways. This study Investigates the effect of blocking one pathway in the drug levels of BMS-986165 in health subjects.

Timeline

Start
2019-10-01
Primary completion
2019-11-19
Completion
2019-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject CRAVACITINIB Small molecule — —
Subject diflunisal Small molecule — —

Indications

No indication recorded.